As of 2025-07-02, the EV/EBITDA ratio of Sangamo Therapeutics Inc (SGMO) is -0.83. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SGMO's latest enterprise value is 103.43 mil USD. SGMO's TTM EBITDA according to its financial statements is -125.00 mil USD. Dividing these 2 quantities gives us the above SGMO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.7x - 13.6x | 13.4x |
| Forward P/E multiples | 22.0x - 30.9x | 25.6x |
| Fair Price | (11.47) - (7.07) | (10.15) |
| Upside | -2218.5% - -1406.1% | -1975.6% |
| Date | EV/EBITDA |
| 2025-07-01 | -0.77 |
| 2025-06-30 | -0.83 |
| 2025-06-27 | -0.83 |
| 2025-06-26 | -0.86 |
| 2025-06-25 | -0.90 |
| 2025-06-24 | -0.78 |
| 2025-06-23 | -0.62 |
| 2025-06-20 | -0.67 |
| 2025-06-18 | -0.73 |
| 2025-06-17 | -0.72 |
| 2025-06-16 | -0.75 |
| 2025-06-13 | -0.73 |
| 2025-06-12 | -0.75 |
| 2025-06-11 | -0.79 |
| 2025-06-10 | -0.78 |
| 2025-06-09 | -0.77 |
| 2025-06-06 | -0.81 |
| 2025-06-05 | -0.73 |
| 2025-06-04 | -0.73 |
| 2025-06-03 | -0.75 |
| 2025-06-02 | -0.70 |
| 2025-05-30 | -0.68 |
| 2025-05-29 | -0.67 |
| 2025-05-28 | -0.66 |
| 2025-05-27 | -0.66 |
| 2025-05-23 | -0.70 |
| 2025-05-22 | -0.74 |
| 2025-05-21 | -0.75 |
| 2025-05-20 | -0.75 |
| 2025-05-19 | -0.75 |
| 2025-05-16 | -0.69 |
| 2025-05-15 | -0.65 |
| 2025-05-14 | -0.63 |
| 2025-05-13 | -0.67 |
| 2025-05-12 | -1.22 |
| 2025-05-09 | -1.13 |
| 2025-05-08 | -1.17 |
| 2025-05-07 | -1.03 |
| 2025-05-06 | -0.96 |
| 2025-05-05 | -1.17 |
| 2025-05-02 | -1.18 |
| 2025-05-01 | -1.21 |
| 2025-04-30 | -1.27 |
| 2025-04-29 | -1.17 |
| 2025-04-28 | -1.21 |
| 2025-04-25 | -1.29 |
| 2025-04-24 | -1.35 |
| 2025-04-23 | -1.23 |
| 2025-04-22 | -1.27 |
| 2025-04-21 | -1.20 |